Open AccessPhase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients
Author(s) -
Suekane Shigetaka,
Nishitani Masaaki,
Noguchi Masanori,
Komohara Yoshihiro,
Kokubu Takako,
Naitoh Masayasu,
Honma Shigenori,
Yamada Akira,
Itoh Kyogo,
Matsuoka Kei,
Kanayama Hiroomi
Publication year - 2007
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2007.00631.x
Subject(s) - medicine , peripheral blood mononuclear cell , peptide vaccine , vaccination , renal cell carcinoma , immunology , cytotoxic t cell , immunotherapy , cytokine , immune system , antigen , epitope , biology , in vitro , biochemistry
The aim of this clinical trial was to investigate the toxicity and immunological responses of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients. Patients were confirmed to be human leukocyte antigen (HLA)‐A24 or HLA‐A2 positive and had histologically confirmed renal cell carcinoma. Ten patients were enrolled in the present study. The peptides to be administered were determined based on the presence of peptide‐specific cytotoxic T lymphocyte precursors in peripheral blood mononuclear cells (PBMC) and peptide‐specific IgG in the plasma of cancer patients. Patients received subcutaneous injections of four different peptides (3 mg/peptide) every 2 weeks. Vaccinations were well tolerated without any major adverse events. A minimal increase in peptide‐specific interferon‐γ production in postvaccination PBMC was observed, regardless of higher levels of cytotoxic T lymphocyte activity in prevaccination PBMC. In contrast, an increase in peptide‐specific IgG levels of postvaccination (sixth) plasma was observed in the majority of patients. After progression, five patients received interleukin‐2 therapy and continuous vaccination, with survival of 31, 25, 23, 17, and 15 months, but interleukin‐2 did not impede humoral responses boosted by the vaccination. These results encourage further clinical trials of personalized peptide vaccinations. ( Cancer Sci 2007; 98: 1965–1968)